Manufacturer of Controlled Substances; Notice of Registration, 587 [2010-33265]

Download as PDF Federal Register / Vol. 76, No. 3 / Wednesday, January 5, 2011 / Notices company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: December 23, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–33270 Filed 1–4–11; 8:45 am] investigated Cambrex Charles City, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: December 23, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [FR Doc. 2010–33265 Filed 1–4–11; 8:45 am] Manufacturer of Controlled Substances; Notice of Registration BILLING CODE 4410–09–P By Notice dated August 2, 2010, and published in the Federal Register on September 1, 2010, (75 FR 53721), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: DEPARTMENT OF LABOR Drug Schedule jlentini on DSKJ8SOYB1PROD with NOTICES Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Phenylacetone (8501) .................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Dextropropoxyphene, bulk ........... (non-dosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Raw Opium (9600) ....................... Opium extracts (9610) .................. Opium, powdered (9639) ............. Opium, granulated (9640) ............ Poppy Straw (9650) ..................... Oxymorphone (9652) ................... Concentrate of Poppy Straw (9670). Sufentanil (9740) .......................... Fentanyl (9801) ............................ II II II II II II II II II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex Charles City, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has VerDate Mar<15>2010 16:26 Jan 04, 2011 Jkt 223001 Comment Request for Information Collection for Extension With Revisions Employment and Training Administration, Labor. ACTION: Notice. AGENCY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(2)(A)]. This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Employment and Training Administration is soliciting comments concerning the collection of data about High Growth and Community-Based Job Training Grants OMB No. 1205–0465, which expires: 5/31/2011. A copy of the proposed information collection request (ICR) can be obtained by contacting the office listed below in the ADDRESSES section of this notice. DATES: Written comments must be submitted to the office listed in the ADDRESSES section below on or before March 7, 2011. ADDRESSES: Submit written comments to Megan Baird, Room N–4643, SUMMARY: PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 587 Employment and Training Administration, 200 Constitution Avenue, NW., Washington, DC 20210. Telephone number: 202–693–3949 (this is not a toll-free number). Fax: 202–693– 3890. E-mail: businessrelations@dol.gov. Please reference OMB Control Number 1205–0465 in the subject line of the email. SUPPLEMENTARY INFORMATION: I. Background: This document provides the justification for the request by the Department of Labor, Employment and Training Administration (ETA) for an extension with revisions of OMB-approved quarterly progress reporting requirements for the High Growth Job Training Initiative (HGJTI) grants and the Community-Based Job Training (CBJT) grants. The OMB-approved HGJTI and CBJTG quarterly progress reporting requirements, OMB No. 1205– 1465, expire May 31, 2011. Through the extension with renewal request, ETA will require grantees to submit standardized quarterly progress reports summarizing the number and types of participants served by grantees, the number of exiters, the number of participants engaged in training activities, and some participant outcomes. To calculate the common performance measures for each grantee and the grant programs as a whole, ETA will also require grantees to submit quarterly standardized records for exiters that contain the minimum number of elements needed to calculate common performance measure outcomes. These progress reporting requirements align with outcome categories identified in the SGAs used to award HGJTI and CBJT grants. The collection of this data helps ETA report the impact of these funds and provides ETA with more comprehensive information on the status of individual grants and individuals that receive services and find employment through these grants. The accuracy, reliability, and comparability of program reports submitted by grantees using federal funds are fundamental elements of good public administration and are necessary tools for maintaining and demonstrating system integrity. The use of a standard set of data elements, definitions, and specifications at all levels of the workforce system, including the HGJTI and CBJT grants, helps improve the quality of performance information that is received by ETA. This data also helps ETA provide more targeted technical assistance to support improvement of grantee outcomes. ETA will continue to provide HGJTI and CBJT grantees with a reporting system, the Enterprise E:\FR\FM\05JAN1.SGM 05JAN1

Agencies

[Federal Register Volume 76, Number 3 (Wednesday, January 5, 2011)]
[Notices]
[Page 587]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-33265]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated August 2, 2010, and published in the Federal 
Register on September 1, 2010, (75 FR 53721), Cambrex Charles City, 
Inc., 1205 11th Street, Charles City, Iowa 50616, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the following basic classes of controlled 
substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  ...........................
Lisdexamfetamine (1205)....................  II
Methylphenidate (1724).....................  II
Phenylacetone (8501).......................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Dextropropoxyphene, bulk...................  II
(non-dosage forms) (9273)..................
Morphine (9300)............................  II
Thebaine (9333)............................  II
Raw Opium (9600)...........................  II
Opium extracts (9610)......................  II
Opium, powdered (9639).....................  II
Opium, granulated (9640)...................  II
Poppy Straw (9650).........................  II
Oxymorphone (9652).........................  II
Concentrate of Poppy Straw (9670)..........  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for sale to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cambrex Charles City, Inc. to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Cambrex Charles City, Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance 
with 21 CFR 1301.33, the above named company is granted registration as 
a bulk manufacturer of the basic classes of controlled substances 
listed.

    Dated: December 23, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-33265 Filed 1-4-11; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.